CoChat
Sign Up
Cited by 3,270Immune cells in cancerCancer Immunotherapy and BiomarkersCancer Cells and Metastasis

The Tumor Microenvironment Innately Modulates Cancer Progression

Open access
Hinshaw, Dominique C., Shevde, Lalita A.·2019·Cancer Research
DOI 10.1158/0008-5472.can-18-3962PMC PMC6744958
Open this paper in CoChat — free account

Abstract

Cancer development and progression occurs in concert with alterations in the surrounding stroma. Cancer cells can functionally sculpt their microenvironment through the secretion of various cytokines, chemokines, and other factors. This results in a reprogramming of the surrounding cells, enabling them to play a determinative role in tumor survival and progression. Immune cells are important constituents of the tumor stroma and critically take part in this process. Growing evidence suggests that the innate immune cells (macrophages, neutrophils, dendritic cells, innate lymphoid cells, myeloid-derived suppressor cells, and natural killer cells) as well as adaptive immune cells (T cells and B cells) contribute to tumor progression when present in the tumor microenvironment (TME). Cross-talk between cancer cells and the proximal immune cells ultimately results in an environment that fosters tumor growth and metastasis. Understanding the nature of this dialog will allow for improved therapeutics that simultaneously target multiple components of the TME, increasing the likelihood of favorable patient outcomes.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/0008-5472.can-18-3962

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • The tumour microenvironment influences cancer development and prognosis.

    “which is consistent with research demonstrating the tumour microenvironment’s influence on cancer development22 and prognosis.”

    From Foundation Model for Cancer Imaging Biomarkers (2024) · cites this paper as [22]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 92

  1. [1]McGuirk P and Mills KH, Pathogen-specific regulatory T cells provoke a shift in the Th1/Th2 paradigm in immunity to infectious diseases. Trends Immunol, 2002 23(9): p. 450– 5. 12200067
  2. [2]Yang L and Zhang Y, Tumor-associated macrophages: from basic research to clinical application. J Hematol Oncol, 2017 10(1): p. 58. 28241846 PMC5329931
  3. [3]Chen H,, Macrophage peroxisome proliferator-activated receptor gamma deficiency delays skin wound healing through impairing apoptotic cell clearance in mice. Cell Death Dis, 2015 6: p. e1597. 25590807 PMC4669743
  4. [4]Peiseler M and Kubes P, Macrophages play an essential role in trauma-induced sterile inflammation and tissue repair. Eur J Trauma Emerg Surg, 2018 44(3): p. 335– 349. 29666944
  5. [5]Varol C, Mildner A, and Jung S, Macrophages: development and tissue specialization. Annu Rev Immunol, 2015 33: p. 643– 75. 25861979
  6. [6]Qin L,, NCOA1 Directly Targets M-CSF1 Expression to Promote Breast Cancer Metastasis. Cancer Res, 2014 74(13): p. 3477– 88. 24769444 PMC4083628
  7. [7]Kim J and Bae JS, Tumor-Associated Macrophages and Neutrophils in Tumor Microenvironment. Mediators Inflamm, 2016 2016: p. 6058147. 26966341 PMC4757693
  8. [8]Cardoso AP,, Macrophages stimulate gastric and colorectal cancer invasion through EGFR Y(1086), c-Src, Erk1/2 and Akt phosphorylation and smallGTPase activity. Oncogene, 2014 33(16): p. 2123– 33. 23644655
  9. [9]Wang N,, CXCL1 derived from tumor-associated macrophages promotes breast cancer metastasis via activating NF-kappaB/SOX4 signaling. Cell Death Dis, 2018 9(9): p. 880. 30158589 PMC6115425
  10. [10]Zhao X,, Prognostic significance of tumor-associated macrophages in breast cancer: a meta-analysis of the literature. Oncotarget, 2017 8(18): p. 30576– 30586. 28427165 PMC5444766
  11. [11]Goswami S,, Macrophages promote the invasion of breast carcinoma cells via a colony-stimulating factor-1/epidermal growth factor paracrine loop. Cancer Res, 2005 65(12): p. 5278– 83. 15958574
  12. [12]Wyckoff J,, A paracrine loop between tumor cells and macrophages is required for tumor cell migration in mammary tumors. Cancer Res, 2004 64(19): p. 7022– 9. 15466195
  13. [13]Funes SC,, Implications of macrophage polarization in autoimmunity. Immunology, 2018 154(2): p. 186– 195. 29455468 PMC5980179
  14. [14]Zheng X,, Redirecting tumor-associated macrophages to become tumoricidal effectors as a novel strategy for cancer therapy. Oncotarget, 2017 8(29): p. 48436– 48452. 28467800 PMC5564660
  15. [15]Petrova V,, The hypoxic tumour microenvironment. Oncogenesis, 2018 7(1): p. 10. 29362402 PMC5833859
  16. [16]Hanna A,, Inhibition of Hedgehog signaling reprograms the dysfunctional immune microenvironment in breast cancer. Oncoimmunology, 2019 8(3): p. 1548241. 30723576 PMC6350695
  17. [17]Peinado H,, Pre-metastatic niches: organ-specific homes for metastases. Nat Rev Cancer, 2017 17(5): p. 302– 317. 28303905
  18. [18]Doak GR, Schwertfeger KL, and Wood DK, Distant Relations: Macrophage Functions in the Metastatic Niche. Trends Cancer, 2018 4(6): p. 445– 459. 29860988 PMC5990045
  19. [20]Motta JM and Rumjanek VM, Sensitivity of Dendritic Cells to Microenvironment Signals. J Immunol Res, 2016 2016: p. 4753607. 27088097 PMC4819111
  20. [22]Basit F,, Human Dendritic Cell Subsets Undergo Distinct Metabolic Reprogramming for Immune Response. Front Immunol, 2018 9: p. 2489. 30455688 PMC6230993
  21. [23]Fridlender ZG,, Polarization of tumor-associated neutrophil phenotype by TGF-beta: “N1” versus “N2” TAN. Cancer Cell, 2009 16(3): p. 183– 94. 19732719 PMC2754404
  22. [24]Chaput N,, The Janus face of dendritic cells in cancer. Oncogene, 2008 27(45): p. 5920– 31. 18836473
  23. [25]Aspord C,, Breast cancer instructs dendritic cells to prime interleukin 13-secreting CD4+ T cells that facilitate tumor development. J Exp Med, 2007 204(5): p. 1037– 47. 17438063 PMC2118566
  24. [26]Tran Janco JM,, Tumor-infiltrating dendritic cells in cancer pathogenesis. J Immunol, 2015 194(7): p. 2985– 91. 25795789 PMC4369768
  25. [27]Michea P,, Adjustment of dendritic cells to the breast-cancer microenvironment is subset specific. Nat Immunol, 2018 19(8): p. 885– 897. 30013147
  26. [28]Wang J,, The clinical significance of tumor-infiltrating neutrophils and neutrophil-to-CD8+ lymphocyte ratio in patients with resectable esophageal squamous cell carcinoma. J Transl Med, 2014 12: p. 7. 24397835 PMC3895663
  27. [29]Deniset JF and Kubes P, Recent advances in understanding neutrophils. F1000Res, 2016 5: p. 2912. 28105328 PMC5225409
  28. [30]Uribe-Querol E and Rosales C, Neutrophils in Cancer: Two Sides of the Same Coin. J Immunol Res, 2015 2015: p. 983698. 26819959 PMC4706937
  29. [31]Cools-Lartigue J,, Neutrophil extracellular traps in cancer progression. Cell Mol Life Sci, 2014 71(21): p. 4179– 94. 25070012 PMC7096049
  30. [32]Jin W,, Tumor-Infiltrating NETs Predict Postsurgical Survival in Patients with Pancreatic Ductal Adenocarcinoma. Ann Surg Oncol, 2018. 30374923
  31. [33]Fridlender ZG and Albelda SM, Tumor-associated neutrophils: friend or foe? Carcinogenesis, 2012 33(5): p. 949– 55. 22425643
  32. [34]Demers M,, Priming of neutrophils toward NETosis promotes tumor growth. Oncoimmunology, 2016 5(5): p. e1134073. 27467952 PMC4910712
  33. [35]He M,, Peritumoral stromal neutrophils are essential for c-Met-elicited metastasis in human hepatocellular carcinoma. Oncoimmunology, 2016 5(10): p. e1219828. 27853643 PMC5087290
  34. [36]Schauer C,, Aggregated neutrophil extracellular traps limit inflammation by degrading cytokines and chemokines. Nat Med, 2014 20(5): p. 511– 7. 24784231
  35. [37]Pillay J,, Immune suppression by neutrophils and granulocytic myeloid-derived suppressor cells: similarities and differences. Cell Mol Life Sci, 2013 70(20): p. 3813– 27. 23423530 PMC3781313
  36. [39]Rodriguez PC,, Arginase I-producing myeloid-derived suppressor cells in renal cell carcinoma are a subpopulation of activated granulocytes. Cancer Res, 2009 69(4): p. 1553– 60. 19201693 PMC2900845
  37. [40]Youn JI,, Characterization of the nature of granulocytic myeloid-derived suppressor cells in tumor-bearing mice. J Leukoc Biol, 2012 91(1): p. 167– 81. 21954284 PMC3250305
  38. [41]Gabrilovich DI, Ostrand-Rosenberg S, and Bronte V, Coordinated regulation of myeloid cells by tumours. Nat Rev Immunol, 2012 12(4): p. 253– 68. 22437938 PMC3587148
  39. [43]Kumar V,, The Nature of Myeloid-Derived Suppressor Cells in the Tumor Microenvironment. Trends Immunol, 2016 37(3): p. 208– 220. 26858199 PMC4775398
  40. [44]Condamine T,, Regulation of tumor metastasis by myeloid-derived suppressor cells. Annu Rev Med, 2015 66: p. 97– 110. 25341012 PMC4324727
  41. [45]Condamine T,, Lectin-type oxidized LDL receptor-1 distinguishes population of human polymorphonuclear myeloid-derived suppressor cells in cancer patients. Sci Immunol, 2016 1(2). PMC5391495 28417112
  42. [47]Hossain F,, Inhibition of Fatty Acid Oxidation Modulates Immunosuppressive Functions of Myeloid-Derived Suppressor Cells and Enhances Cancer Therapies. Cancer Immunol Res, 2015 3(11): p. 1236– 47. 26025381 PMC4636942
  43. [48]Stabile H,, Role of Distinct Natural Killer Cell Subsets in Anticancer Response. Front Immunol, 2017 8: p. 293. 28360915 PMC5352654
  44. [49]Glasner A,, NKp46 Receptor-Mediated Interferon-gamma Production by Natural Killer Cells Increases Fibronectin 1 to Alter Tumor Architecture and Control Metastasis. Immunity, 2018 48(2): p. 396– 398. PMC5823842 29466761
  45. [50]Imai K,, Natural cytotoxic activity of peripheral-blood lymphocytes and cancer incidence: an 11-year follow-up study of a general population. Lancet, 2000 356(9244): p. 1795– 9. 11117911
  46. [51]Langers I,, Natural killer cells: role in local tumor growth and metastasis. Biologics, 2012 6: p. 73– 82. 22532775 PMC3333822
  47. [52]Maurer S,, Platelet-mediated shedding of NKG2D ligands impairs NK cell immune-surveillance of tumor cells. Oncoimmunology, 2018 7(2): p. e1364827. 29308299 PMC5749664
  48. [53]Nair S and Dhodapkar MV, Natural Killer T Cells in Cancer Immunotherapy. Front Immunol, 2017 8: p. 1178. 29018445 PMC5614937
  49. [54]Krijgsman D, Hokland M, and Kuppen PJK, The Role of Natural Killer T Cells in Cancer-A Phenotypical and Functional Approach. Front Immunol, 2018 9: p. 367. 29535734 PMC5835336
  50. [55]Gebremeskel S,, Natural killer T cell activation overcomes immunosuppression to enhance clearance of postsurgical breast cancer metastasis in mice. Oncoimmunology, 2015 4(3): p. e995562. 25949924 PMC4404817
  51. [56]Renukaradhya GJ,, Type I NKT cells protect (and type II NKT cells suppress) the host’s innate antitumor immune response to a B-cell lymphoma. Blood, 2008 111(12): p. 5637– 45. 18417738 PMC2424159
  52. [57]Flores-Borja F,, Crosstalk between Innate Lymphoid Cells and Other Immune Cells in the Tumor Microenvironment. J Immunol Res, 2016 2016: p. 7803091. 27882334 PMC5110869
  53. [58]von Burg N,, Activated group 3 innate lymphoid cells promote T-cell-mediated immune responses. Proc Natl Acad Sci U S A, 2014 111(35): p. 12835– 40. 25136120 PMC4156721
  54. [59]Kyoizumi S,, Fate Decision Between Group 3 Innate Lymphoid and Conventional NK Cell Lineages by Notch Signaling in Human Circulating Hematopoietic Progenitors. J Immunol, 2017 199(8): p. 2777– 2793. 28893953 PMC5632839
  55. [60]Seillet C, Belz GT, and Huntington ND, Development, Homeostasis, and Heterogeneity of NK Cells and ILC1. Curr Top Microbiol Immunol, 2016 395: p. 37– 61. 26305047
  56. [61]Jovanovic IP,, Interleukin-33/ST2 axis promotes breast cancer growth and metastases by facilitating intratumoral accumulation of immunosuppressive and innate lymphoid cells. Int J Cancer, 2014 134(7): p. 1669– 82. 24105680
  57. [62]van Beek JJP,, Innate Lymphoid Cells in Tumor Immunity. Biomedicines, 2016 4(1). PMC5344245 28536374
  58. [63]Fuchs A,, Intraepithelial type 1 innate lymphoid cells are a unique subset of IL-12- and IL-15-responsive IFN-gamma-producing cells. Immunity, 2013 38(4): p. 769– 81. 23453631 PMC3634355
  59. [64]Mattner J and Wirtz S, Friend or Foe? The Ambiguous Role of Innate Lymphoid Cells in Cancer Development. Trends Immunol, 2017 38(1): p. 29– 38. 27810463
  60. [65]Pickup MW, Mouw JK, and Weaver VM, The extracellular matrix modulates the hallmarks of cancer. EMBO Rep, 2014 15(12): p. 1243– 53. 25381661 PMC4264927
  61. [66]Lund AW,, Lymphatic vessels regulate immune microenvironments in human and murine melanoma. J Clin Invest, 2016 126(9): p. 3389– 402. 27525437 PMC5004967
  62. [67]Podgrabinska S,, Inflamed lymphatic endothelium suppresses dendritic cell maturation and function via Mac-1/ICAM-1-dependent mechanism. J Immunol, 2009 183(3): p. 1767– 79. 19587009 PMC4410990
  63. [68]Lakins MA,, Cancer-associated fibroblasts induce antigen-specific deletion of CD8 (+) T Cells to protect tumour cells. Nat Commun, 2018 9(1): p. 948. 29507342 PMC5838096
  64. [69]Faradji A,, Phase I study of liposomal MTP-PE-activated autologous monocytes administered intraperitoneally to patients with peritoneal carcinomatosis. J Clin Oncol, 1991 9(7): p. 1251– 60. 2045866
  65. [70]Hennemann B,, Phase I trial of adoptive immunotherapy of cancer patients using monocyte-derived macrophages activated with interferon gamma and lipopolysaccharide. Cancer Immunol Immunother, 1998 45(5): p. 250– 6. 9439648 PMC11037564
  66. [71]Stevenson HC,, Fate of gamma-interferon-activated killer blood monocytes adoptively transferred into the abdominal cavity of patients with peritoneal carcinomatosis. Cancer Res, 1987 47(22): p. 6100– 3. 3117363
  67. [72]Ries CH,, Targeting tumor-associated macrophages with anti-CSF-1R antibody reveals a strategy for cancer therapy. Cancer Cell, 2014 25(6): p. 846– 59. 24898549
  68. [73]Ostuni R,, Macrophages and cancer: from mechanisms to therapeutic implications. Trends Immunol, 2015 36(4): p. 229– 39. 25770924
  69. [74]Quail DF and Joyce JA, Molecular Pathways: Deciphering Mechanisms of Resistance to Macrophage-Targeted Therapies. Clin Cancer Res, 2017 23(4): p. 876– 884. 27895033 PMC5453188
  70. [75]De Palma M,, Tumor-targeted interferon-alpha delivery by Tie2-expressing monocytes inhibits tumor growth and metastasis. Cancer Cell, 2008 14(4): p. 299– 311. 18835032
  71. [76]Boczkowski D,, Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo. J Exp Med, 1996 184(2): p. 465– 72. 8760800 PMC2192710
  72. [77]Cao J,, DNA vaccines targeting the encoded antigens to dendritic cells induce potent antitumor immunity in mice. BMC Immunol, 2013 14: p. 39. 23941509 PMC3751307
  73. [78]Hamilton DH,, Immunological targeting of tumor cells undergoing an epithelial-mesenchymal transition via a recombinant brachyury-yeast vaccine. Oncotarget, 2013 4(10): p. 1777– 90. 24125763 PMC3858563
  74. [79]van Willigen WW,, Dendritic Cell Cancer Therapy: Vaccinating the Right Patient at the Right Time. Front Immunol, 2018 9: p. 2265. 30327656 PMC6174277
  75. [80]Saxena M and Bhardwaj N, Re-Emergence of Dendritic Cell Vaccines for Cancer Treatment. Trends Cancer, 2018 4(2): p. 119– 137. 29458962 PMC5823288
  76. [81]Lesterhuis WJ,, Dendritic cell vaccines in melanoma: from promise to proof? Crit Rev Oncol Hematol, 2008 66(2): p. 118– 34. 18262431
  77. [82]Ocana A,, Neutrophils in cancer: prognostic role and therapeutic strategies. Mol Cancer, 2017 16(1): p. 137. 28810877 PMC5558711
  78. [84]Connolly EC, Freimuth J, and Akhurst RJ, Complexities of TGF-beta targeted cancer therapy. Int J Biol Sci, 2012 8(7): p. 964– 78. 22811618 PMC3399319
  79. [85]Fleming V,, Targeting Myeloid-Derived Suppressor Cells to Bypass Tumor-Induced Immunosuppression. Front Immunol, 2018 9: p. 398. 29552012 PMC5840207
  80. [86]Iclozan C,, Therapeutic regulation of myeloid-derived suppressor cells and immune response to cancer vaccine in patients with extensive stage small cell lung cancer. Cancer Immunol Immunother, 2013 62(5): p. 909– 18. 23589106 PMC3662237
  81. [87]Weber R,, Myeloid-Derived Suppressor Cells Hinder the Anti-Cancer Activity of Immune Checkpoint Inhibitors. Front Immunol, 2018 9: p. 1310. 29942309 PMC6004385
  82. [88]Yang Y,, Phase I Study of Random Healthy Donor-Derived Allogeneic Natural Killer Cell Therapy in Patients with Malignant Lymphoma or Advanced Solid Tumors. Cancer Immunol Res, 2016 4(3): p. 215– 24. 26787822
  83. [89]Veluchamy JP,, The Rise of Allogeneic Natural Killer Cells As a Platform for Cancer Immunotherapy: Recent Innovations and Future Developments. Front Immunol, 2017 8: p. 631. 28620386 PMC5450018
  84. [90]Tang X,, First-in-man clinical trial of CAR NK-92 cells: safety test of CD33-CAR NK-92 cells in patients with relapsed and refractory acute myeloid leukemia. Am J Cancer Res, 2018 8(6): p. 1083– 1089. 30034945 PMC6048396
  85. [91]Rezvani K,, Engineering Natural Killer Cells for Cancer Immunotherapy. Mol Ther, 2017 25(8): p. 1769– 1781. 28668320 PMC5542803
  86. [92]Bolourian A and Mojtahedi Z, Possible damage to immune-privileged sites in natural killer cell therapy in cancer patients: side effects of natural killer cell therapy. Immunotherapy, 2017 9(3): p. 281– 288. 28231718
  87. [94]Steinman RM, Hawiger D, and Nussenzweig MC, Tolerogenic dendritic cells. Annu Rev Immunol, 2003 21: p. 685– 711. 12615891
  88. [96]Conejo-Garcia JR, Rutkowski MR, and Cubillos-Ruiz JR, State-of-the-art of regulatory dendritic cells in cancer. Pharmacol Ther, 2016 164: p. 97– 104. 27118338 PMC4942379
  89. [97]Guilliams M,, Unsupervised High-Dimensional Analysis Aligns Dendritic Cells across Tissues and Species. Immunity, 2016 45(3): p. 669– 684. 27637149 PMC5040826
  90. [98]Collin M, McGovern N, and Haniffa M, Human dendritic cell subsets. Immunology, 2013 140(1): p. 22– 30. 23621371 PMC3809702
  91. [99]Chen K,, Tissue-resident dendritic cells and diseases involving dendritic cell malfunction. Int Immunopharmacol, 2016 34: p. 1– 15. 26906720 PMC4818737
  92. [100]Gueguen C,, Changes in markers associated with dendritic cells driving the differentiation of either TH2 cells or regulatory T cells correlate with clinical benefit during allergen immunotherapy. J Allergy Clin Immunol, 2016 137(2): p. 545– 58. 26522402

Cited by

Sorted by citations

Authors
Hinshaw, D. C., & Shevde, L. A.
Affiliations
University of Alabama at Birmingham (US)
Corresponding author
Shevde, Lalita A.
ORCID
Venue
Cancer Research
Publisher
American Association for Cancer Research (AACR)
Published
2019-09-13
Volume
79
Issue
18
Pages
4557-4566
ISSN
  • 0008-5472 (ISSN-L)
  • 1538-7445
DOI
10.1158/0008-5472.can-18-3962
PMC
PMC6744958
OpenAlex
W2966710588
Cited by
3,270
References
8
Citations by year
2026: 231 · 2025: 449 · 2024: 628 · 2023: 738 · 2022: 753 · 2021: 359 · 2020: 98 · 2019: 10
FWCI
26.66
Type
journal article
Language
en
Open access
Locations
  • Cancer Research (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
Funders
  • National Cancer Institute (R01CA169202, P30CA013148)
  • National Institute of Allergy and Infectious Diseases (T32AI007051)
Topics
  • Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
Keywords
tumor microenvironment, tumor progression, tumor stroma, innate immune cells, adaptive immune cells, macrophages, neutrophils, dendritic cells, innate lymphoid cells, myeloid-derived suppressor cells, natural killer cells, T cells, B cells, cytokines, chemokines, tumor-immune cell crosstalk, metastasis, cancer immunotherapy
MeSH terms
Animals, Humans, Immunity, Innate, Neoplasms, Tumor Microenvironment

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review